Core Viewpoint - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. reported stable revenue and growth in net profit for the first half of 2025, while continuing to focus on its core business and enhancing product lines through external resources [1][2]. Financial Performance - The company achieved operating revenue of 1.239 billion yuan, remaining flat compared to the same period last year [1]. - Net profit attributable to shareholders was 38.81 million yuan, representing a year-on-year increase of 6.65% [1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 36.85 million yuan, showing a significant year-on-year growth of 36.34% [1]. Business Development - The company is advancing its core business and has made progress in the production and research of biopharmaceuticals and health products [1]. - Beijing Huasu received a drug production license from the Beijing Drug Administration, expanding its production scope to include the active pharmaceutical ingredient Benidipine, which enhances the company's product portfolio [1]. - The cost of the core product, Benidipine tablets, has steadily decreased compared to annual plans and previous years, improving its market competitiveness [1]. Research and Development - The company is actively progressing its research and development projects, with several products receiving acceptance notifications from the National Medical Products Administration [2]. - Key products under development include Tramadol tablets, Oxycodone sustained-release tablets, and Arolol tablets, among others [2]. - The company is also focusing on new product selection and project initiation, aiming to advance according to its R&D plans [2]. Sales Performance - Sales of the main product, Bisoprolol fumarate tablets, remained stable compared to the previous year, while Benidipine tablets continued to grow [2]. - Revenue from the strategic product Oxycodone injection increased by over 90% year-on-year [2]. - The company successfully won the bid for the tenth batch of national centralized procurement for Naloxone injection [2]. Future Outlook - As a designated producer of narcotic drugs, the company has a range of analgesic and psychiatric products, leveraging its integrated advantages in active pharmaceutical ingredients and formulations [2]. - The company plans to develop the Oxycodone product line as a significant area of growth alongside its cardiovascular products [2].

山东中关村医药科技发展有限公司所属的位于 威海市惠河路-90-1 号至惠河路-90-4 号 四幢工业房地产 市场价值估价报告 信源(房估)字第 2025080175 号 估价项目名称:山东中关村医药科技发展有限公司所属的位于威海市惠 河路-90-1 号至惠河路-90-4 号四幢工业房地产市场价 值评估 估价委托人:山东华素制药有限公司 房地产估价机构:山东信源土地房地产资产评估咨询有限公司 注册房地产估价师:孙仙洁(3720210167)、王雯(3720250001) 二、估价对象:估价对象为威海市惠河路-90-1 号至惠河路-90-4 号四幢 工业房地产的房屋所有权及分摊土地使用权,评估范围内建筑物面积合计为 19709.15 平方米,共用宗地面积为 132233.00 平方米,使用期限:国有建设 用地使用权 2014年01月 09 日起 2064年 01月 08 日止。本次评估分摊土地使 用权面积为 40677. 44 m²。（详细见附表 1） 估价报告作业日期:2025年8月6日 www.sdxvng 邮箱: xy@sdxypg.com 电话:0631-5335733 致估价委托方函 山东华素制药有限公 ...

房地产抵押估价报告 估价报告编号:威华地[2025]房字第 20373 号 估价项目名称:北京市朝阳区吉庆里9 号楼、10 号楼地下一层商业 1、3、6、9共4 套商业用房地产抵押价值的评估 估 价 委 托 人:烟台银行股份有限公司 威海分行 36 评 061016 房地产估价机构:威海 2年12月 12月 22 估有限公司 注册房地产估价师:王青松 注册号: 3720110067 董建英 注册号: 3720110068 估价报告出具日期:2025年8月13日 威海华地土地房地产评估有限公司 北京市朝阳区吉庆里 9 号楼、10 号楼地下一层商业 1、3、6、9共 套商业用房地产抵押价值的评估 致估价委托人函 烟台银行股份有限公司威海分行: 承蒙委托,我公司委派专业人员对委托评估的房地产进行了实地查 勘,遵循公认的估价原则,按照严谨的估价程序,依据有关法律法规和估 价标准,在对估价对象进行合理的假设条件下,运用适宜的估价方法,对 估价对象房地产在价值时点的价值进行了专业分析、测算和判断,评估工 作现已完成,报告主要内容如下: 估价目的:为确定房地产抵押贷款额度提供参考依据而评估房地产 抵押价值。 估价对象: 北 ...

Core Viewpoint - Company reported stable revenue and robust profit growth in the first half of 2025, with a focus on strengthening its position in the biopharmaceutical sector and expanding its product matrix through innovation [1][2]. Financial Performance - In the first half of 2025, the company achieved revenue of 1.239 billion yuan, essentially flat year-on-year; however, net profit attributable to shareholders increased by 6.65% to 38.81 million yuan, and net profit excluding non-recurring items rose by 36.34% to 36.85 million yuan [1]. Product Development and Sales - The strategic product, "Hydromorphone Hydrochloride Injection," saw revenue growth exceeding 90% year-on-year, becoming a key pillar for the company [2]. - The company is expanding its product line with ongoing research and development, including applications for sustained-release hydromorphone tablets and acetaminophen-hydromorphone tablets, which are currently under review [2][3]. - The company is also focusing on both formulation sales and raw material production, establishing partnerships with other pharmaceutical companies to enhance its competitive edge in the hydromorphone market [3]. Market Position and Strategy - The company has solidified its market position in traditional therapeutic areas such as cardiovascular diseases, with core products like "Benidipine Hydrochloride Tablets" capturing 55% of the market share in its category [4]. - The company has successfully expanded its market presence in non-collection markets, achieving over 20% growth in recent years for its core products [4]. - The company has also made significant strides in the OTC channel, with products like "Huasu Tablets" and "Naloxone Sublingual Tablets" receiving recognition at health conferences [5]. Regulatory Environment and Future Outlook - Recent changes in national procurement policies may benefit the company by allowing for brand-based volume reporting, which could enhance its market share in key therapeutic areas [6]. - The company is actively developing a comprehensive pain management product matrix, including new drugs and raw materials, which is expected to bolster its market position [7]. - The company has attracted attention from various investment institutions, indicating strong market recognition and potential for future growth [8].

关于 2025 年半年度各项资产计提减值的公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2025-100 北京中关村科技发展（控股）股份有限公司 关于 2025 年半年度各项资产计提减值的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本次计提各项资产减值准备情况概述 基于谨慎性原则，公司对截至 2025 年 6 月 30 日合并报表范围内可能发生 资产减值损失的有关资产计提资产减值准备。计提资产减值准备的资产范围包 括：应收账款、其他应收款，本报告期其他资产未计提减值准备。具体情况如 下： 注：上表计提金额以正数列示，转回金额以负数列示。 本次计提资产减值准备计入的报告期间为 2025 年 1 月 1 日至 2025 年 6 月 30 日。 二、本次计提资产减值的依据及相关说明 | 资产名称 | 应收账款、其他应收款 | | --- | --- | | 本次计提减值金额（万元） | 1,342.77 | | 本次资产减值准备计提依据 | 对于应收账款，无论是否存在重大融资成分，本公司均按照 | | | 整个存续期的预期信用损 ...

北京中关村科技发展（控股）股份有限公司 2025 年半年度财务报告 共 113 页 北京中关村科技发展（控股）股份有限公司 2025 年半年度财务报告 （未经审计） 二〇二五年八月 1 北京中关村科技发展（控股）股份有限公司 2025 年半年度财务报告 共 113 页 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 非流动资产： | | | | 发放贷款和垫款 | | | | 债权投资 | | | | 其他债权投资 | | | | 长期应收款 | | | | 长期股权投资 | 2,273,191.28 | 2,319,021.04 | | 其他权益工具投资 | 3,006,596.09 | 3,006,596.09 | | 其他非流动金融资产 | | | | 投资性房地产 | 205,529,706.09 | 210,587,298.99 | | 固定资产 | 843,018,955.53 | 840,88 ...

合并及公司资产负债表 2025年06月30日 般) 股份有限公司 单位:人民币元 | | 期末数 | | 期初数 | | | --- | --- | --- | --- | --- | | | 合并 | 母公司 | 合并 | 母公司 | | 流动资产: | | | | | | 货币资金 | 162.864.214.49 | 2.882.003.44 | 151,393,279.42 | 16.269.401.23 | | 交易性金融资产 | 2.173,439.66 | 2,042,169.66 | 2.173.439.66 | 2,042,169.66 | | 应收票据 | 1,267,200.00 | | 5,346,000.00 | | | 应收账款 | 1.024.015.850.13 | | 956.462.878.91 | | | 应收款项融资 | 108.700.490.58 | | 117.975.011.18 | | | 预付款项 | 71.129.046.11 | 3,500,000.00 | 40.706,446.49 | | | 其他应收款 | 58.391,824.38 | 1.84 ...

关于公司为山东华素向烟台银行申请5,000 万元融资授信提供担保的公告 共 5 页 证券代码：000931 证券简称：中关村 公告编号：2025-098 北京中关村科技发展（控股）股份有限公司 关于公司为山东华素向烟台银行申请 5,000 万元融资授信 提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2025 年 8 月 25 日召开第九届董事会第三次会议，审议通过《关于公司为山东华素向烟 台银行申请 5,000 万元融资授信提供担保的议案》，具体情况如下： 一、担保情况概述 经第八届董事会 2024 年度第九次临时会议审议通过，公司全资子公司北京 中关村四环医药开发有限责任公司（以下简称：四环医药）之控股子公司北京华 素制药股份有限公司（以下简称：北京华素）之全资子公司山东华素制药有限公 司（以下简称：山东华素）向烟台银行股份有限公司威海分行（以下简称：烟台 银行）申请额度不超过 2,000 万元人民币的融资授信，期限为 1 年，公司以其商 业用房地产的房屋所有权以及分摊的土地使用权 ...

关于公司和山东中关村为山东华素向威海银行申请敞口额度8,000万元的融资授信提供担保的公告 共 5 页 证券代码：000931 证券简称：中关村 公告编号：2025-097 北京中关村科技发展（控股）股份有限公司 关于公司和山东中关村为山东华素向威海银行申请敞口 额度 8,000 万元的融资授信提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）于 2025 年 8 月 25 日召开第九届董事会第三次会议，审议通过《关于公司和山东中关村为 山东华素向威海银行申请敞口额度 8,000 万元的融资授信提供担保的议案》，具 体情况如下： 一、担保情况概述 经第八届董事会第七次会议审议通过，公司全资子公司北京中关村四环医药 开发有限责任公司（以下简称：四环医药）之控股子公司北京华素制药股份有限 公司（以下简称：北京华素）之全资子公司山东华素制药有限公司（以下简称： 山东华素）向威海银行股份有限公司初村支行（以下简称：威海银行）申请额度 不超过 8,000 万元人民币的融资授信，期限为 1 年，山东中关 ...

。 北京中关村科技发展（控股）股份有限公司2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | △ 资金占用方名称 | 占用方与上市 公司的关联关 系 | 上市公司核算 2025年期初占用资 的会计科目 | 金余额 | 2025年1-6月占用 累计发生金额 (不含利息) | 2025年1-6月占用 资金的利息(如 有) | 累计发生金额 | 2025年6月30日 期末占用资金余 占用形成原因 额 | | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 控股股东、实际控制人发具钢 945675 属企业 | | | | | | | | | | 非经营性占用 | | 小计 | | Santa | | | | | | | - | | | 前控股股东、实际控制人及其 树属交亦 | | | | | | | | | | 非经营性占用 | | 小计 | | | | | | | | | | | | 其他关联方及其附属企业 | | | | | | | | | | 非经营性占用 | | 小计 ...